Vitamin B12 and Folate IV Therapy: Methylation, Evidence and Why the Route Decides the Answer

In short: vitamin B12 and folate have an unusually solid evidence base — for treating documented deficiency, by intramuscular injection or high-dose oral tablet. The intravenous route is the exception rather than the upgrade: the FDA-approved label for cyanocobalamin injection instructs prescribers to avoid it, because 50 to 98% of an injected dose can appear in the urine within 48 hours and an IV bolus forfeits the depot effect that makes intramuscular dosing work. Beyond deficiency, the picture narrows sharply. Three large outcome trials — HOPE-2, NORVIT and SEARCH, together randomising more than 22,000 patients — lowered homocysteine by 22 to 28% and did not reduce major vascular events. A 2021 meta-analysis of 16 trials in 6,276 people without deficiency found no effect on cognition, mood or fatigue. What remains is a real, cheap, high-yield intervention for the substantial minority of people who are actually deficient — and a marketing story about "methylation support" that the trial record does not carry.

B12 and folate arrive in the IV clinic with better credentials than most infusion ingredients. They are established treatments for named conditions, they sit in every hospital formulary, and unlike glutathione or alpha-lipoic acid nobody disputes that humans need them. That is precisely what makes this category harder to read. The question is not whether the molecules work — they demonstrably do, in deficiency — but whether the delivery route, the dose and the population being treated bear any relationship to the evidence that made them respectable.

What B12 and folate do, and what "methylation" means

Vitamin B12 (cobalamin) is a cobalt-containing vitamin that humans cannot synthesise and obtain almost exclusively from animal-derived food. It serves as cofactor for exactly two enzymes in human metabolism: methionine synthase, which remethylates homocysteine to methionine, and methylmalonyl-CoA mutase, which handles the breakdown of odd-chain fatty acids and several amino acids. Two reactions, but both sit at metabolic chokepoints, which is why deficiency produces effects as varied as macrocytic anaemia, peripheral neuropathy and cognitive change.

Folate (vitamin B9) is the carrier that supplies the one-carbon units those reactions consume. Its active circulating form, 5-methyltetrahydrofolate, donates the methyl group that methionine synthase transfers to homocysteine — a reaction that requires B12 as the intermediary. This is why the two vitamins are inseparable clinically and why the Knowledge Bank treats them as a linked pair rather than two independent entries.

"Methylation" in this context means one specific thing: the cycle that converts methionine to S-adenosylmethionine (SAM), the universal methyl donor for several hundred reactions — DNA and histone methylation, phospholipid and neurotransmitter synthesis, and the disposal of surplus nicotinamide, which is where this pathway quietly intersects with NAD+ infusion practice. When the cycle stalls, homocysteine accumulates upstream. That accumulation is measurable, which is what made homocysteine such an attractive therapeutic target — and, as the trial record below shows, such an instructive cautionary tale.

The route question: why IV is the weakest option here

For nearly every other compound covered in this Journal, intravenous delivery is the pharmacological argument: it bypasses first-pass metabolism and achieves plasma concentrations the oral route cannot. For B12 that logic inverts.

The FDA-approved prescribing information for cyanocobalamin injection specifies intramuscular and deep subcutaneous administration, and states directly: "Avoid using the intravenous route. Use of this product intravenously will result in almost all of the vitamin being lost in the urine." The same label quantifies it — within 48 hours after an injection of 100 or 1,000 mcg, 50 to 98% of the dose may appear in the urine, the major portion within the first eight hours.

The reason is that B12 replacement depends on retention, not on peak concentration. An intramuscular injection forms a depot that is absorbed gradually, allowing binding to transcobalamin and storage in the liver, which is what sustains a three-monthly maintenance interval. A rapid intravenous bolus saturates the binding proteins at once and presents a large unbound fraction to the kidney, which clears it. Hydroxocobalamin is retained better than cyanocobalamin after intramuscular injection — lower urinary excretion over the following days — which is why it, not cyanocobalamin, is the parenteral form used in the United Kingdom.

Two further numbers put IV dosing in perspective. The daily parenteral requirement in adult nutrition support — the amount in the FDA-approved adult multivitamin used in parenteral nutrition — is 5 mcg of cyanocobalamin and 600 mcg of folic acid per day. Wellness drips commonly contain 1,000 to 5,000 mcg of B12: between 200 and 1,000 times the physiological parenteral requirement, the surplus largely cleared within hours. And the NICE evidence review underpinning the 2024 guideline on B12 deficiency discusses intramuscular and oral replacement at length; intravenous administration does not feature in it at all.

None of this makes B12 in a combined infusion pointless — a multi-ingredient formulation such as the Myers' cocktail includes it for reasons of formulation completeness, not depot repletion. It does mean that an IV drip is not a treatment for B12 deficiency, and should not be offered as one.

The one-carbon cycle in practice

Methionine synthase requires methylcobalamin to accept a methyl group from 5-methyltetrahydrofolate and pass it to homocysteine, regenerating methionine. Methionine is then activated to SAM, which donates methyl groups and becomes S-adenosylhomocysteine, hydrolysed back to homocysteine. The cycle turns continuously; B12 and folate are the two points at which it can jam.

When B12 is unavailable, folate becomes trapped as 5-methyltetrahydrofolate — the "methyl trap" — because the only reaction that can release it requires B12. Tissue folate is functionally unavailable even when serum folate is normal, which explains why B12 deficiency produces the same megaloblastic anaemia as folate deficiency. Simultaneously, methylmalonyl-CoA accumulates on the second B12-dependent pathway, raising methylmalonic acid: a marker specific to B12 rather than folate, and one of the reasons functional testing outperforms a serum B12 level alone.

This biochemistry is not in dispute. What it does not establish is that adding B12 and folate to a person whose cycle is not jammed produces any clinical effect — the inference that carries most "methylation support" marketing, and the one the trials below were designed to test.

Clinical evidence graded by indication

Read indication by indication, the record is unusually clear-cut: strong where a deficiency exists, consistently negative where it does not.

Deficiency treatment is where this pair earns its reputation, and the effect sizes are the kind other IV compounds can only aspire to: correcting a genuine deficiency reverses anaemia and can halt or partially reverse neurological damage. NICE notes that symptoms may start improving within two weeks though full response can take up to three months, and that deficiency should not be ruled out on the absence of anaemia or macrocytosis alone. The population matters too — deficiency is common among long-term metformin users, people on proton pump inhibitors, strict vegans, and those with autoimmune gastritis, where reported B12 deficiency rates reach 13.3% against 2.8% in controls.

The route comparison has been settled more recently than most practitioners assume. A 2025 systematic review and meta-analysis in Frontiers in Pharmacology pooled 25 studies (16 in meta-analysis, 6,098 participants) and found serum cobalamin rose by a mean 402.6 pg/mL with no statistically significant difference between oral, sublingual and intramuscular routes, and homocysteine fell comparably across all three. Certainty was moderate for the B12 outcome and low for homocysteine, with substantial heterogeneity — so this supports oral as a reasonable option, not as universally interchangeable. NICE still prioritises intramuscular replacement where absorption or adherence is in doubt.

The homocysteine story is the most instructive failure in this field. The biomarker responds exactly as predicted — HOPE-2 cut homocysteine by roughly 22%, SEARCH by 28% — and the clinical events did not follow. HOPE-2 randomised 5,522 patients with vascular disease or diabetes to folic acid 2.5 mg, B6 50 mg and B12 1 mg for five years with no effect on the primary composite; NORVIT found no benefit after myocardial infarction; SEARCH randomised 12,064 myocardial infarction survivors to folic acid 2 mg plus B12 1 mg and found no significant effect on major vascular events. A cumulative meta-analysis of 24 randomised trials in 57,952 people leaves a non-significant result for major adverse cardiac events, mortality, MI and stroke. Stroke remains the one outcome where a modest signal recurs across analyses, including HOPE-2 — genuinely unresolved, and not a licence to treat.

Non-deficient supplementation is the claim most often attached to a drip and the one with the cleanest negative answer. The 2021 Nutrients meta-analysis restricted itself to people without overt deficiency or advanced neurological disease and found nothing across 16 trials and 6,276 participants.

MTHFR, methylfolate and the genotype pitch

The MTHFR C677T variant is real, common and does what it is said to do biochemically: it produces a thermolabile enzyme with reduced activity, which can raise plasma homocysteine. The inferential leap happens next — that carriers therefore require the pre-methylated form of folate, and that testing should guide supplementation.

The American College of Medical Genetics and Genomics addressed this in a practice guideline recommending against routine MTHFR polymorphism testing, citing minimal clinical utility. Head-to-head trials comparing L-5-methyltetrahydrofolate with folic acid have shown comparable homocysteine reduction, with 5-MTHF producing similar or modestly higher red-cell folate; a randomised trial in recurrent pregnancy loss stratified by MTHFR genotype found no significant difference in outcome between the two forms.

There are respectable formulation reasons to prefer 5-MTHF — it bypasses the reduction steps entirely and does not contribute to unmetabolised folic acid in circulation. What is not supported is the marketing structure built on top: genotype testing as a gateway, and the implication that carriers are failing to "methylate" without a specific product.

Dosing, testing and infusion protocols

Deficiency treatment in the UK follows British National Formulary schedules, as the BSH guideline recommends. In practice that means hydroxocobalamin 1 mg intramuscularly, given as a loading course — typically every other day for two weeks where there is no neurological involvement, or on alternate days until no further improvement occurs where there is — followed by maintenance of 1 mg every two to three months, lifelong where the cause is malabsorption or intrinsic factor antibody positivity. NICE additionally supports oral cyanocobalamin, from 50 mcg daily for dietary deficiency up to 1,000 mcg daily as a minimum for malabsorption, while prioritising the intramuscular route where adherence, absorption or rapid deterioration is a concern.

Testing matters as much as dosing here. Serum cobalamin is the first-line test, with a cut-off of 148 pmol/L (200 ng/L) in the presence of strong clinical suspicion, but BSH guidance is explicit that no single test is a gold standard and that cobalamin and folate should be assessed together. In the indeterminate zone, plasma methylmalonic acid is more specific and total homocysteine more sensitive, both interpreted against renal function; in a study of 11,833 samples, holotranscobalamin achieved the highest area under the curve (0.92) for subclinical deficiency, ahead of MMA (0.91), serum B12 (0.90) and homocysteine (0.78). Folate deficiency is defined by BSH at a serum folate below 7 nmol/L (3 µg/L).

For intravenous formulations specifically, there is no established protocol, because the pivotal evidence does not use this route. The only defensible anchor is the parenteral nutrition standard — 5 mcg cyanocobalamin and 600 mcg folic acid per day in the adult multivitamin — which is what the body can actually use when delivered intravenously.

Safety — including the one rule that matters most

Never give folate before excluding B12 deficiency. Folate corrects the megaloblastic anaemia while the neurological lesion progresses, so the most visible sign disappears and subacute combined degeneration of the spinal cord advances unchecked. The FDA-approved label warns that folic acid may prevent the anaemia but allow progression of subacute combined degeneration, with the potential for incapacitating and irreversible spinal cord damage. This is the reason BSH recommends assaying cobalamin and folate concurrently, and it applies directly to any combined formulation.

Form-specific contraindications. Cyanocobalamin is contraindicated in Leber's hereditary optic neuropathy, where the cyanide moiety may worsen optic nerve damage; hydroxocobalamin or methylcobalamin are used instead. Known sensitivity to cobalt or to cobalamin itself is also a contraindication, and anaphylactic reactions to parenteral B12 have been reported — the label advises an intradermal test dose where sensitivity is suspected.

Hypokalaemia during initial repletion. When severe deficiency is corrected, the burst of erythropoiesis consumes potassium and can produce clinically relevant hypokalaemia in the first days of treatment. Electrolyte monitoring during initial replacement in severely anaemic patients is standard, and is the kind of detail that separates deficiency treatment from a wellness infusion.

What excess does not do. Both vitamins are water-soluble with wide safety margins, and no established toxicity threshold exists for B12. That is often presented as an argument for large doses; it is more accurately an argument that large doses are unnecessary, since the surplus is excreted rather than stored.

B12 and folate formulations in practice

The practitioner assessing a methylation formulation is really assessing three separate questions, and conflating them is where the category goes wrong. Is there a deficiency? If yes, the evidence is strong and the treatment is intramuscular hydroxocobalamin or high-dose oral cyanocobalamin, with folate assessed alongside it. Is the goal a downstream clinical outcome — cardiovascular events, cognition, energy — in someone who is not deficient? The trials answered that, at scale, in the negative. Is the aim formulation completeness within a broader infusion concept, at doses appropriate to what the body retains parenterally? That is a legitimate design rationale, provided it is not described as deficiency treatment.

The IVIXIR methylation concept sits in the third category, and that is exactly how it should be read: a formulation built around folate and B12 as the linked pair the biochemistry describes, alongside the amino acid and antioxidant concepts in the series. What it is not, and what no infusion is, is a substitute for testing someone with suspected deficiency and treating them by the route the guidelines actually specify. Holding that distinction — mechanism, evidence, route, and what a formulation is honestly for — is the standard EFBA applies across the range.